Clinical trial of a new treatment for the hepatocellular carcinoma patients with liver cirrhosis
- Conditions
- Hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000024496
- Lead Sponsor
- niversity of Tsukuba
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10
Not provided
(1)Acute hepatitis (2)Patients with HIV infection (3)Patients with a past history of cerebrovascular disease or cardiovascular disease (4)Bone marrow transplant recipients and immunosuppressed patients (5)Patient with plasma protein deficiency (eg. IgA deficiency) (6)Patients complicated with cerebrovascular disease, cardiovascular disease, pulmonary disease, renal disease, gastroenterological disease, hematological disease, and neurological or psychiatric disease (7)Patients with a cancer in other organs (8)Patients with HbA1c(NGSP) higher than 8.0 (9)Patients who is currently pregnant or consider pregnancy prior to the study (10)Patients who participated in another clinical trial within 6 months and received medications having pharmacologic effects on improving liver function or increasing platelet counts (11)Patients who have taken or who is currentry taking thrombopoietic agent (12)Patients with a past history of taking the Eltrombopag (13)Patients with allergic reaction to this medicine (14)Patients with allergic reaction to other medications (15)Patients with a past history of arterial or venous thromboembolism In addition, the patient who is judged to be inappropriate for this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method progression free survival
- Secondary Outcome Measures
Name Time Method